Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Want to cut your energy bills? Here’s how five experts are doing it 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
BURLINGTON, Mass., March 02, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to provide an update on business operations and report its fiscal year 2016 financial results on Thursday, March 9, 2017, at 4:30 p.m. ET.
The dial-in number for the conference call is (855) 770-0022 for domestic participants and (908) 982-4677 for international participants, with Conference ID # 77592180. A live webcast of the conference call can also be accessed through the “Investors” tab on the Flexion Therapeutics website. A webcast replay will be available online after the call.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA of the knee. The company's lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contacts: Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected] Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected] Investor Contact: David Carey Lazar Partners LTD T: 212-867-1768 [email protected]
